Open label, Phase I, multicenter study, 2 arms with a dose escalation part and a dose expansion part.
Intervention
Arm A: 3 days on/ 4 days off, max 6 cycles
Arm B: continuous dosing
Key outcome parameters
Safety and tolerability of IAG933
Key inclusion criteria
Advanced (unresectable or metastatic) mesothelioma, or solid tumors harboring NF2/LATS1/LATS2 truncating mutations or deletions or functional YAP/TAZ fusions
Patient must be willing to undergo a new tumor biopsy at screening/baseline, and again during therapy on this study
ECOG performance status 0 or 1
Key exclusion criteria
Presence of symptomatic CNS metastases, or CNS tumors or metastases that require local CNS- directed therapy, or increasing doses of corticosteroids 2 weeks prior to study entry.
Wij maken op deze website gebruik van cookies om het gebruik van de website te
vergemakkelijken, de prestaties en gebruikerservaring te verbeteren en de
relevantie van het aanbod op deze website te verhogen.
Lees ons Cookies &
Privacystatement.